Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

TGF-β2 dictates disseminated tumour cell fate in target organs through TGF-β-RIII and p38α/β signalling.

Bragado P, Estrada Y, Parikh F, Krause S, Capobianco C, Farina HG, Schewe DM, Aguirre-Ghiso JA.

Nat Cell Biol. 2013 Nov;15(11):1351-61. doi: 10.1038/ncb2861. Epub 2013 Oct 27.

2.

Intrinsic TGF-β2-triggered SDF-1-CXCR4 signaling axis is crucial for drug resistance and a slow-cycling state in bone marrow-disseminated tumor cells.

Nakamura T, Shinriki S, Jono H, Guo J, Ueda M, Hayashi M, Yamashita S, Zijlstra A, Nakayama H, Hiraki A, Shinohara M, Ando Y.

Oncotarget. 2015 Jan 20;6(2):1008-19.

3.

TGF-β-induced growth inhibition in B-cell lymphoma correlates with Smad1/5 signalling and constitutively active p38 MAPK.

Bakkebø M, Huse K, Hilden VI, Smeland EB, Oksvold MP.

BMC Immunol. 2010 Nov 23;11:57. doi: 10.1186/1471-2172-11-57.

4.

Mechanisms of mitotic inhibition in corneal endothelium: contact inhibition and TGF-beta2.

Joyce NC, Harris DL, Mello DM.

Invest Ophthalmol Vis Sci. 2002 Jul;43(7):2152-9.

PMID:
12091410
5.
6.
7.

Transforming growth factor beta2 regulates growth and differentiation of pulp cells via ALK5/Smad2/3.

Tai TF, Chan CP, Lin CC, Chen LI, Jeng JH, Chang MC.

J Endod. 2008 Apr;34(4):427-32. doi: 10.1016/j.joen.2008.02.007.

PMID:
18358889
8.
9.

Phenotypic heterogeneity of disseminated tumour cells is preset by primary tumour hypoxic microenvironments.

Fluegen G, Avivar-Valderas A, Wang Y, Padgen MR, Williams JK, Nobre AR, Calvo V, Cheung JF, Bravo-Cordero JJ, Entenberg D, Castracane J, Verkhusha V, Keely PJ, Condeelis J, Aguirre-Ghiso JA.

Nat Cell Biol. 2017 Feb;19(2):120-132. doi: 10.1038/ncb3465. Epub 2017 Jan 23.

10.

Involvement of P38MAPK in human corneal endothelial cell migration induced by TGF-β(2).

Joko T, Shiraishi A, Akune Y, Tokumaru S, Kobayashi T, Miyata K, Ohashi Y.

Exp Eye Res. 2013 Mar;108:23-32. doi: 10.1016/j.exer.2012.11.018. Epub 2012 Dec 17.

PMID:
23257207
11.

Activation of the pro-survival phosphatidylinositol 3-kinase/AKT pathway by transforming growth factor-beta1 in mesenchymal cells is mediated by p38 MAPK-dependent induction of an autocrine growth factor.

Horowitz JC, Lee DY, Waghray M, Keshamouni VG, Thomas PE, Zhang H, Cui Z, Thannickal VJ.

J Biol Chem. 2004 Jan 9;279(2):1359-67. Epub 2003 Oct 23.

12.

Therapeutic targeting of the focal adhesion complex prevents oncogenic TGF-beta signaling and metastasis.

Wendt MK, Schiemann WP.

Breast Cancer Res. 2009;11(5):R68. doi: 10.1186/bcr2360.

13.
14.

Effect of TGF-β on ocular surface epithelial cells.

Benito MJ, Calder V, Corrales RM, García-Vázquez C, Narayanan S, Herreras JM, Stern ME, Calonge M, Enríquez-de-Salamanca A.

Exp Eye Res. 2013 Feb;107:88-100. doi: 10.1016/j.exer.2012.11.017. Epub 2012 Dec 7.

PMID:
23220729
15.

Corticosteroids stimulate selectively transforming growth factor (TGF)-beta receptor type III expression in transdifferentiating hepatic stellate cells.

Wickert L, Abiaka M, Bolkenius U, Gressner AM.

J Hepatol. 2004 Jan;40(1):69-76. Erratum in: J Hepatol. 2004 Aug;41(2):359.

PMID:
14672616
16.

Betaglycan induces TGF-beta signaling in a ligand-independent manner, through activation of the p38 pathway.

Santander C, Brandan E.

Cell Signal. 2006 Sep;18(9):1482-91. Epub 2006 Jan 18.

PMID:
16413747
19.

In the absence of type III receptor, the transforming growth factor (TGF)-beta type II-B receptor requires the type I receptor to bind TGF-beta2.

del Re E, Babitt JL, Pirani A, Schneyer AL, Lin HY.

J Biol Chem. 2004 May 21;279(21):22765-72. Epub 2004 Mar 2.

Supplemental Content

Support Center